NY-WHITE-OPS
23.12.2020 17:08:14 CET | Business Wire | Press release
White Ops (“White Ops” or the “Company”), a global leader in protecting enterprises and internet platforms from digital fraud and abuse, today announced its acquisition by Goldman Sachs Merchant Banking Division, in partnership with ClearSky Security and NightDragon (together, the “Sponsors”). The Sponsors are acquiring the business from previous investors Paladin Capital Group, Grotech Ventures, and other shareholders, and the acquisition follows Goldman Sachs’ and ClearSky’s initial investment in the Company earlier this year . The acquisition has formally closed and terms of the transaction were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201223005385/en/
The acquisition will support White Ops in its next phase of growth and further accelerate its expansion into new markets. The Company's core focus is to protect enterprises from sophisticated bot attacks and fraud across the domains of cybersecurity, digital advertising, and marketing, serving some of the largest enterprises and internet platforms. This year, as more companies moved to digital, White Ops was called upon on behalf of its customers to verify the humanity of more than 10 trillion interactions per week and growing, providing an incredibly broad and deep platform to stop nefarious activity across the internet. The company grew the number of customers it serves by 40% and employees of the company grew by 25% to 170.
“Goldman Sachs, ClearSky, and NightDragon are ideal partners to support the next phase of the Company’s evolution and growth across multiple markets, use cases and geographies,” said Tamer Hassan, CEO and co-founder of White Ops. “Their continued support of our mission to disrupt the economics of cybercrime, global network of relationships, and market expertise provides a very strong foundation to execute on our vision to enable collective protection for the internet.”
“We have been very pleased with the Company’s performance since our initial investment and we’re delighted to build on our current partnership, especially as White Ops continues to benefit from consumers’ shift to digital and clients increasingly require protection,” said Anthony Arnold, Managing Director at Goldman Sachs. “We look forward to supporting management in their next phase of growth.”
“White Ops’ highly differentiated technology platform and scaled signal collection footprint helps its clients protect against a wide range of sophisticated fraud types,” said Matthew Popper, Managing Director at Goldman Sachs. “We look forward to working with management and our partners at ClearSky and NightDragon to accelerate the Company’s expansion into new markets.”
"As fraud and abuse become increasingly prevalent across the digital ecosystem, enterprises and internet platforms require sophisticated threat protection now more than ever. White Ops has proven that it can stop fraud and abuse at tremendous scale," said Jay Leek, Managing Partner of ClearSky. "We have spent a lot of time with their leadership team over the past year and have been impressed with the strength and quality of their platform. We look forward to partnering to continue to build on the Company’s leadership position in the industry."
"Through our experience in engaging with hundreds of enterprises and their cybersecurity teams, we know that automated attacks on applications creating fraud and abuse is a critical point of risk to every security and marketing team," said Dave DeWalt, Founder and Managing Director at NightDragon. "We look forward to partnering with the team at White Ops to help clients across a range of industries."
In addition to representatives from Goldman Sachs, Jay Leek will join the Board of Directors representing ClearSky and Dave DeWalt will join the Board of Directors representing NightDragon and serve as Vice Chairman of the Company.
Morgan Stanley & Co. LLC acted as financial advisor to White Ops. Legal counsel was provided to White Ops by Cooley LLP.
The Sponsors were advised by Momentum Cyber. Legal counsel was provided to the Sponsors by Sullivan & Cromwell LLP and Wilson Sonsini Goodrich & Rosati.
Bad actors with millions of sophisticated bots at their disposal cause fraud at the rate of tens of billions of dollars a year against companies across the globe. These sophisticated bots live on consumer and enterprise devices, sharing browsing history and habits with real humans, which makes them especially difficult to detect. White Ops’ multilayered detection methodology, advanced algorithms, Satori Threat Intelligence and Research Team , and massive scale can detect and prevent these automated attacks at every level of sophistication, protecting customers’ sensitive data, reputation, compliance, bottom line and customer experience as they grow their digital business. These capabilities enabled White Ops to play a leading role in taking down 3ve , one of the largest fraud botnets to date, through collective protection and bringing together the largest private sector collaboration in history, including the FBI, Google, Facebook and many others in the industry. White Ops also recently uncovered ICEBUCKET , the largest and widest Connected TV (CTV) related fraud operation. In addition, White Ops recently announced availability of its products in the AWS Cloud Marketplace and the Snowflake Data Marketplace to provide customers even more ways to access the Company’s platform.
White Ops’ Fraud Mitigation Platform solves top cybersecurity pain points through its product offerings:
- Application Integrity - Protects sites and applications from digital fraud and abuse including account takeover attacks, new account fraud, fraudulent transactions and sensitive content scraping, preventing costly fraud losses while preserving user privacy and frictionless digital experiences.
- Marketing Integrity - Protects digital marketing investments from fraud and abuse including paid media, lead generation, and retargeting, preventing fraudulent traffic from entering marketing platforms to ensure efficiency and boost ROI.
- Advertising Integrity - Protects digital media and advertising from fraud and abuse within desktop, mobile, and CTV environments for trusted inventory and human-only impressions for more effective advertising.
To learn more about White Ops’ perspective on how this investment further advances their mission, read this blog post from CEO and co-founder Tamer Hassan: https://www.whiteops.com/blog/our-next-chapter
About White Ops
White Ops is a cybersecurity company that collectively protects global enterprises and internet platforms from digital fraud and abuse. We verify the humanity of more than 10 trillion interactions per week protecting our customers sensitive data, reputation, compliance, bottom line and customer experience as they grow their digital business. To learn more visit www.whiteops.com
About Goldman Sachs Merchant Banking Division
Founded in 1869, The Goldman Sachs Group, Inc. is a leading global investment banking, securities and investment management firm. Goldman Sachs Merchant Banking Division (MBD) is the primary center for the firm’s long-term principal investing activity. MBD is one of the leading private capital investors in the world with investments across private equity, infrastructure, private debt, growth equity and real estate.
About ClearSky
ClearSky is a venture capital/growth equity firm that has been operating since 2012 with offices across the United States. ClearSky invests in companies that offer transformative security solutions with a specific focus on cybersecurity, critical infrastructure security, privacy, data governance and compliance. The firm’s world-class dedicated security team has a proven track record with over 60 years of security investing and practitioner experience. ClearSky also has a highly distinguished advisory board consisting of diverse business leaders and a Fortune 500 CISO Board of Advisors that is unmatched in the industry. For more information, visit http://clear-sky.com/
About NightDragon
NightDragon is an investment firm focused on investing in growth and late-stage companies within the cybersecurity industry. Its flexible model allows it to lead or co-invest alongside leading venture capital and private equity firms in the pursuit of driving growth and increasing shareholder value. NightDragon is unique in providing deep operational expertise in cybersecurity gained by its founders Dave DeWalt and Ken Gonzalez from years serving as senior executives leading technology companies such as Documentum, EMC, Siebel Systems (Oracle), McAfee, Mandiant, Avast, and FireEye. For more information, visit www.NightDragon.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201223005385/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom